ESLA Estrella Immunopharma, Inc. - Common Stock
$0.77
Price · Aug 19, 2026
Fundamentals as of May 18, 2026
52W Range
$1–$3
4% of range
Analyst Rating
BUY
7 analysts
Price Target
$12
+1458% upside
P/E (TTM)
-4.5
ROE
—
Net Profit Margin
—
ESLA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.77
Market Cap
—
P/E (TTM)
-4.5
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$1 – $3
ESLA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
ESLA
Peer Median
P/E (TTM)
-4.5
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
ESLA
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
ESLA
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
ESLA
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
ESLA
Peer Median
ESLA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-08-18
Low
$12.00
High
$12.00
Median target
$12.00
+1458.4%
Mean target
$12.00
+1458.4%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.05%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| Dec. 31, 2025 | $-0.35 | $-0.18 | -0.17% |
| Sept. 30, 2025 | $-0.13 | $-0.19 | 0.06% |
| June 30, 2025 | $-0.35 | $-0.18 | -0.17% |
| March 31, 2025 | $-0.13 | $-0.19 | 0.06% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ESLA | — | -4.5 | — | — | — | — |
| BYSI | — | — | — | — | 3.1% | — |
| LTRN | — | -1.9 | — | — | — | — |
| GRML | — | — | — | — | -104.9% | — |
| LITS | $16M | -1.0 | 33.8% | — | -81.7% | — |
| GRDX | $20M | -1.1 | — | -17634.4% | -68.6% | -1813.6% |
| DYAI | — | -4.1 | -11.6% | — | — | — |
| KYNB | $36M | 0.2 | -78.3% | 2848.6% | -143.5% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 11
| Metric | Trend | 2025 |
|---|---|---|
| Prepaid Expense | $292.7K | |
| Current Assets | $2M | |
| Total Assets | $3M | |
| Current Liabilities | $14M | |
| Total Liabilities | $14M | |
| Common Stock | $3.8K | |
| Paid-in Capital | $27M | |
| Retained Earnings | $-37M | |
| Treasury Stock | $598.4K | |
| Stockholders' Equity | $-10M | |
| Liabilities + Equity | $3M |
Valuation (TTM) 3
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $-13M | |
| P/E | -4.5 | |
| Earnings Yield | -22.4% |
Income Statement 11
| Metric | Trend | Q1 2026 |
|---|---|---|
| R&D Expense | $1M | |
| SG&A Expense | $891.8K | |
| Operating Expenses | $2M | |
| Operating Income | $-2M | |
| Pretax Income | $-2M | |
| Net Income | $-2M | |
| EPS (Basic) | $-0.05 | |
| EPS (Diluted) | $-0.05 | |
| Shares (Basic) | 42,121,075 | |
| Shares (Diluted) | 42,121,075 | |
| EBITDA | $-2M |
Balance Sheet 11
| Metric | Trend | Q1 2026 |
|---|---|---|
| Prepaid Expense | $229.8K | |
| Current Assets | $2M | |
| Total Assets | $4M | |
| Current Liabilities | $9M | |
| Total Liabilities | $9M | |
| Common Stock | $4.3K | |
| Paid-in Capital | $35M | |
| Retained Earnings | $-39M | |
| Treasury Stock | $598.4K | |
| Stockholders' Equity | $-5M | |
| Liabilities + Equity | $4M |
Cash Flow 5
| Metric | Trend | Q1 2026 |
|---|---|---|
| Stock-based Comp | $146.7K | |
| Operating Cash Flow | $-7M | |
| Stock Issued | $8M | |
| Net Stock Activity | $8M | |
| Financing Cash Flow | $7M |
Profitability 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -75.1% | |
| ROE | 64.5% |
Liquidity & Solvency 1
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 0.2 |
Valuation (TTM) 3
| Metric | Trend | Q1 2026 |
|---|---|---|
| Net Income TTM | $-15M | |
| P/E | -2.7 | |
| Earnings Yield | -36.8% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 18 filers · $5.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 4 (-2 vs prior Q) | 3 (-3 vs prior Q) | 3 (+2 vs prior Q) | 4 (+1 vs prior Q) | +65K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $4,134,229 | 3,975,220 | 81.43% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $433,526 | 416,852 | 8.54% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $128,912 | 123,954 | 2.54% | Shares |
| VANGUARD GROUP INC | $103,422 | 66,296 | 2.04% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $67,518 | 64,921 | 1.33% | Shares |
| ATW SPAC MANAGEMENT LLC | $46,000 | 40,000 | 0.91% | Shares |
| STATE STREET CORP | $44,982 | 43,252 | 0.89% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $40,664 | 39,100 | 0.80% | Shares |
| NORTHERN TRUST CORP | $36,255 | 34,861 | 0.71% | Shares |
| US BANCORP \DE\ | $20,800 | 20,000 | 0.41% | Shares |
| Maso Capital Partners Ltd | $11,500 | 10,000 | 0.23% | Shares |
| Tower Research Capital LLC (TRC) | $3,440 | 3,308 | 0.07% | Shares |
| BlackRock, Inc. | $2,468 | 2,373 | 0.05% | Shares |
| UBS Group AG | $1,271 | 1,222 | 0.03% | Shares |
| TORONTO DOMINION BANK | $1,133 | 1,089 | 0.02% | Shares |
| WOLVERINE ASSET MANAGEMENT LLC | $487 | 468 | 0.01% | Shares |
| BARCLAYS PLC | $131 | 126 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $2 | 2 | 0.00% | Shares |
Company insiders 3 insiders · 3 officers · 2 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Cheng Liu | Chief Executive Officer | Oct. 30, 2024 A | — | 0 | 0 | $0 |
| Jianwei Li | Co-Chief Executive Officer | March 4, 2022 P | 1,253,730 | 0 | 0 | $0 |
| Jiandong Xu | Chief Financial Officer | Oct. 7, 2025 P | 265,488 | 3 | 0 | $2,594 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Eureka Therapeutics, Inc. (2) | Oct. 30, 2023 | — | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.